How MDMAs Pharmacology and Pharmacokinetics Drive Desired Effects and Harms

Introduction

White situates MDMA (3,4-methylenedioxymethamphetamine) as a widely used illicit recreational drug with a complicated pharmacology that produces both strongly desired effects (elevated mood, energy, bonding, and mild psychedelic sensations) and a range of serious harms (from hyponatraemia and rhabdomyolysis to liver injury, serotonin syndrome, cardiovascular events and death). The compound was synthesised in 1912, saw experimental and limited therapeutic use in the mid-20th century, and is now entrenched in the electronic dance music scene; regulatory scheduling as a DEA Schedule I substance has constrained clinical research and quality control of street products. This paper sets out to review the epidemiology of MDMA use and adverse events, the pharmacologic mechanisms that underlie its desirable and adverse physiological effects, the drug’s pharmacokinetic and interaction profile, and strategies for clinical treatment and harm reduction. The authors frame the review to link mechanistic pharmacology and kinetics with upstream (hormonal, neurotransmitter) and downstream (clinical) outcomes in users exposed in real-world settings such as raves and nightclubs.